/EINPresswire.com/ -- HONG KONG, CHINA -- (Marketwired) -- 08/09/16 -- Hutchison China Meditech Limited (NASDAQ: HCM)

Nasdaq: HCM

Director's Share Dealing

London: Tuesday, August 9, 2016: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) has received notification that the spouse of Mr Christopher Nash, Independent Non-executive Director, has purchased 3,120 and 42 ordinary shares of US$1.00 each in Chi-Med (the "Ordinary Shares") at a price of GBP19.00 and GBP18.99 per share respectively on August 4, 2016.

Following the above transaction, the combined holding of Mr Nash and his spouse is 39,596 Ordinary Shares, representing approximately 0.065% of the current issued share capital of Chi-Med.

The notification set out below is provided in accordance with the requirements of the EU Market Abuse Regulation.

----------------------------------------------------------------------------
1  Details of the person discharging managerial responsibilities/person
   closely associated
----------------------------------------------------------------------------

a) Name                             Ms Rebecca Pynt
----------------------------------------------------------------------------
2  Reason for the notification
----------------------------------------------------------------------------

a) Position/status                  Spouse of Mr Christopher Nash, an
                                    Independent Non-executive Director of
                                    Chi-Med
----------------------------------------------------------------------------

b) Initial notification/Amendment   Initial notification
----------------------------------------------------------------------------
3  Details of the issuer, emission allowance market participant, auction
   platform, auctioneer or auction monitor
----------------------------------------------------------------------------

a) Name                             Hutchison China MediTech Limited
----------------------------------------------------------------------------

b) LEI                              N/A
----------------------------------------------------------------------------
4  Details of the transaction(s): section to be repeated for (i) each type
   of instrument; (ii) each type of transaction; (iii) each date; and (iv)
   each place where transactions have been conducted
----------------------------------------------------------------------------

a) Description of the financial     Ordinary Shares of US$1.00 each DI ISIN:
   instrument, type of instrument   KYG4672N1016 ADS ISIN: US44842L1035
   Identification code
----------------------------------------------------------------------------

b) Nature of the transaction        Acquisition of 3,120 and 42 Ordinary
                                    Shares on August 4, 2016 at a price of
                                    GBP19.00 and GBP18.99 respectively
----------------------------------------------------------------------------

c) Price(s) and volume(s)
                                    ----------------------------------------
                                    Price(s)            Volume(s)
                                    ----------------------------------------
                                    GBP19.00              3,120
                                    ----------------------------------------
                                    GBP18.99               42
                                    ----------------------------------------


----------------------------------------------------------------------------

d)                                  N/A
   Aggregated information

   -Aggregated volume
   -Price


----------------------------------------------------------------------------

e) Date of the transaction          2016-08-04
----------------------------------------------------------------------------

f) Place of the transaction         London Stock Exchange (XLON)
----------------------------------------------------------------------------

NOTES TO EDITORS
About Chi-Med
Chi-Med is an innovative China-based biopharmaceutical company which researches, develops, manufactures and sells pharmaceuticals and healthcare products. Its Innovation Platform, Hutchison MediPharma Limited, focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products in China.

Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 0001). For more information, please visit: www.chi-med.com.

Contacts

Investor Enquiries
Christian Hogg,
CEO                +852 2121 8200

International Media
Enquiries
Anthony Carlisle,
Citigate Dewe      +44 7973 611 888
Rogerson           (Mobile)            anthony.carlisle@cdrconsultancy.co.uk

U.S. Based Media
Enquiries
Brad Miles,        +1 (917) 570 7340
BMC Communications (Mobile)            bmiles@bmccommunications.com

Susan Duffy,       +1 (917) 499 8887
BMC Communications (Mobile)            sduffy@bmccommunications.com

Investor Relations
Brian Korb,        +1 (917) 653 5122
The Trout Group    (Mobile)            bkorb@troutgroup.com

David Dible,
Citigate Dewe      +44 7967 566 919
Rogerson           (Mobile)            david.dible@citigatedr.co.uk

Panmure Gordon (UK)
Limited
Richard Gray /
Andrew Potts       +44 (20) 7886 2500

Contacts:
RNS
Customer
Services
0044-207797-4400
rns@londonstockexchange.com
http://www.rns.com

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.